Thomas Aiello
Pulmonary Disease · Syracuse, NYNPI 1669414421
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $62,500 of the $67,772 with a category attached, or 92.2%. GSK accounts for 96.3% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $40,772 and has fallen 99.8% since, to $74 in 2023. Among pulmonary disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 221 payments — averaging $306.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$65K
- Boehringer Ingelheim$727
- Viiv Healthcare Company$600
- AstraZeneca$260
- Grifols USA, LLC$208
- Inspire Medical Systems, Inc.$112
- plus $592 from 16 others
What the payments were for
- Consulting fees$2340%
- Speaking & faculty fees$62,50092%
- Travel & lodging$1,3982%
- Food & beverage$3,6405%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 116 | $65,274 |
| Boehringer Ingelheim | 44 | $727 |
| Viiv Healthcare Company | 1 | $600 |
| AstraZeneca | 17 | $260 |
| Grifols USA, LLC | 8 | $208 |
| Inspire Medical Systems, Inc. | 1 | $112 |
| Regeneron Healthcare Solutions, Inc. | 4 | $90 |
| Mylan Specialty L.p. | 5 | $81 |
| Sun Pharmaceutical Industries Inc. | 4 | $74 |
| Circassia Inc. | 4 | $59 |
| Genentech USA, Inc. | 2 | $45 |
| Pulmonx Corporation | 1 | $42 |
| Teva Pharmaceuticals USA, Inc. | 3 | $37 |
| Sanofi | 2 | $32 |
| Actelion Pharmaceuticals US, Inc. | 2 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Insmed, Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Optinose US, Inc. | 1 | $14 |
| Philips North America LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$56,104
- ANORO$3,725
- ANORO ELLIPTA$3,600
- Prolastin-C$135
- Inspire Upper Airway Stimulation System$112
How this compares
$67,772 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Syracuse
- Sherif El BayadiSyracuse$571K
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Jack MannBayside$736K
- Raji AyinlaBronx$673K
- Charles PowellNew York$654K
- Nashat RabadiBuffalo$613K
- Craig ThurmJamaica$604K
- Michael MandelLarchmont$589K
- Ali El AtatBrooklyn$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.